2024
Improvements in Sleep Quality in Patients With Major Depressive and Generalized Anxiety Disorders Treated With Individualized, Parcel‐Guided Transcranial Magnetic Stimulation
Tang S, Holle J, Mor S, Dadario N, Ryan M, Teo C, Sughrue M, Yeung J. Improvements in Sleep Quality in Patients With Major Depressive and Generalized Anxiety Disorders Treated With Individualized, Parcel‐Guided Transcranial Magnetic Stimulation. Brain And Behavior 2024, 14: e70088. PMID: 39415644, PMCID: PMC11483549, DOI: 10.1002/brb3.70088.Peer-Reviewed Original ResearchConceptsGeneralized anxiety disorderRepetitive transcranial magnetic stimulationCentral executive networkGeneralized Anxiety Disorder-7Affective disordersBeck Depression InventoryAnxiety disordersTheta burst stimulationTranscranial magnetic stimulationPittsburgh Sleep Quality IndexDorsolateral prefrontal cortexIndividualized repetitive transcranial magnetic stimulationRTMS targetsMagnetic stimulationIntermittent theta burst stimulationFunctional connectivity networksPrefrontal cortexDepressive disorderMajor depressionAffective symptomsQuality of lifeAnxiety symptomsExecutive networkDepression InventorySleep Quality IndexUp-regulated PLA2G10 in cancer impairs T cell infiltration to dampen immunity
Zhang T, Yu W, Cheng X, Yeung J, Ahumada V, Norris P, Pearson M, Yang X, van Deursen W, Halcovich C, Nassar A, Vesely M, Zhang Y, Zhang J, Ji L, Flies D, Liu L, Langermann S, LaRochelle W, Humphrey R, Zhao D, Zhang Q, Zhang J, Gu R, Schalper K, Sanmamed M, Chen L. Up-regulated PLA2G10 in cancer impairs T cell infiltration to dampen immunity. Science Immunology 2024, 9: eadh2334. PMID: 38669316, DOI: 10.1126/sciimmunol.adh2334.Peer-Reviewed Original ResearchConceptsT cell infiltrationT cell exclusionT cellsResistance to anti-PD-1 immunotherapyPoor T-cell infiltrationAnti-PD-1 immunotherapyImmunogenic mouse tumorsT cell mobilizationHuman cancer tissuesTherapeutic immunotherapyCancer immunotherapyMouse tumorsChemokine systemImmunotherapyTumor tissuesImpaired infiltrationTumorLipid metabolitesHuman cancersCancer tissuesInfiltrationA2 groupCancerPLA2G10Up-regulated
2021
Surgical treatment of symptomatic pineal cysts without hydrocephalus—meta-analysis of the published literature
Masina R, Ansaripour A, Beneš V, Berhouma M, Choque-Velasquez J, Eide P, Fedorko S, Fleck S, Hernesniemi J, Koziarski A, Májovský M, Podgorski A, Schroeder H, Teo C, Unterberg A, Yeung J, Kolias A, Santarius T. Surgical treatment of symptomatic pineal cysts without hydrocephalus—meta-analysis of the published literature. Acta Neurochirurgica 2021, 164: 61-77. PMID: 34854993, PMCID: PMC8761144, DOI: 10.1007/s00701-021-05054-0.Peer-Reviewed Original ResearchConceptsSymptomatic pineal cystsPineal cystsCase reportCyst sizeSingle-center retrospective cohortChronic incisional painLarger cyst sizeRetrospective surgical seriesOverall complication rateRole of surgeryVertigo/dizzinessMean cyst sizeLoss of consciousnessObjective outcome assessmentNausea/vomitSupracerebellar infratentorial approachAssessment of outcomesMajority of casesIncisional painComplication rateFocal neurologyGait disturbanceMost patientsPatient characteristicsRetrospective cohortUsing Quicktome for Intracerebral Surgery: Early Retrospective Study and Proof of Concept
Yeung JT, Taylor HM, Nicholas PJ, Young IM, Jiang I, Doyen S, Sughrue ME, Teo C. Using Quicktome for Intracerebral Surgery: Early Retrospective Study and Proof of Concept. World Neurosurgery 2021, 154: e734-e742. PMID: 34358688, DOI: 10.1016/j.wneu.2021.07.127.Peer-Reviewed Original ResearchConceptsIntracerebral surgeryNeurologic deficitsNew postoperative neurologic deficitsCases of leukoencephalopathyNew neurologic deficitsHigh-risk patientsPostoperative neurologic deficitsPostoperative neurologic outcomeIntra-axial tumorsFunctional localizationBrain networksEarlier retrospective studiesCritical brain networksDefault mode networkPostoperative strokeNeurologic outcomeMedian ageNeurological deficitsPreoperative findingsNew deficitsRetrospective studyPostsurgical outcomesIntracranial surgeryNeuronavigation platformStandard neuronavigationOptimal timing of post-operative enoxaparin after neurosurgery: A single institution experience
Briggs RG, Lin YH, Dadario NB, Young IM, Conner AK, Xu W, Tanglay O, Kim SJ, Fonseka RD, Bonney PA, Chakraborty AR, Nix CE, Flecher LR, Yeung JT, Teo C, Sughrue ME. Optimal timing of post-operative enoxaparin after neurosurgery: A single institution experience. Clinical Neurology And Neurosurgery 2021, 207: 106792. PMID: 34233235, DOI: 10.1016/j.clineuro.2021.106792.Peer-Reviewed Original ResearchConceptsDeep vein thrombosisLower extremity deep vein thrombosisExtremity deep vein thrombosisIntracranial tumor resectionVenous thromboembolismAnticoagulant prophylaxisProphylactic enoxaparinTumor resectionImmediate post-operative periodMultivariate binomial logistic regression analysisNon-anticoagulation groupSingle institution experiencePost-operative periodPossible risk factorsPost-operative brain tumor patientsEvidence-based protocolsBrain tumor patientsLogistic regression analysisHigh-grade gliomasBinomial logistic regression analysisVTE complicationsElective craniotomyMedical comorbiditiesPulmonary embolismAdult patientsResection of Symptomatic Pineal Cysts Provides Durable Clinical Improvement: A Breakdown of Presenting Symptoms and Lessons Learned
Yeung JT, Young IM, Profyris C, Katsos K, Sughrue ME, Teo C. Resection of Symptomatic Pineal Cysts Provides Durable Clinical Improvement: A Breakdown of Presenting Symptoms and Lessons Learned. World Neurosurgery 2021, 150: e668-e674. PMID: 33771749, DOI: 10.1016/j.wneu.2021.03.087.Peer-Reviewed Original ResearchConceptsSymptomatic pineal cystsPineal cystsSurgical resectionClinical improvementDurable clinical improvementExhaustive conservative managementNon-headache symptomsDurable symptomatic reliefYears of agePresenting symptomConservative managementSymptomatic patientsSurgical candidacySymptomatic reliefVisual disturbancesClinical outcomesPatient populationRadiographic changesCerebral aqueductRetrospective analysisResectionPatientsVariable symptomsCystsHeadacheRadical Exenteration of the Skull Base for End-Stage, Locally Advanced Sinonasal Malignancies: Challenging the Dictum of Unresectability
Yeung JT, Caminer DM, Young IM, Sughrue ME, Teo C. Radical Exenteration of the Skull Base for End-Stage, Locally Advanced Sinonasal Malignancies: Challenging the Dictum of Unresectability. World Neurosurgery 2021, 150: e102-e107. PMID: 33647490, DOI: 10.1016/j.wneu.2021.02.092.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultCarcinomaCarcinoma, Adenoid CysticChildEsthesioneuroblastoma, OlfactoryFemaleHumansMaleMaxillary Sinus NeoplasmsMiddle AgedNasopharyngeal CarcinomaNeoplasm StagingNeurofibrosarcomaNeurosurgical ProceduresNose NeoplasmsOsteosarcomaParanasal Sinus NeoplasmsProgression-Free SurvivalSalvage TherapySarcomaSkull BaseSquamous Cell Carcinoma of Head and NeckSurvival RateYoung AdultConceptsAdvanced sinonasal cancerSinonasal cancerPerioperative complicationsSalvage surgeryIntracranial involvementSingle-center retrospective reviewAdvanced sinonasal malignanciesAdvanced sinonasal tumorsDetails of chemotherapyRadical salvage surgerySalvage surgical resectionRole of surgeryPrior surgeryOverall survivalPatient demographicsSurgical resectionRetrospective reviewAggressive diseasePalliative careSinonasal malignanciesSurvival outcomesSurgical approachTreatment optionsIntracranial invasionSinonasal tumorsAnatomy and White Matter Connections of the Parahippocampal Gyrus
Lin YH, Dhanaraj V, Mackenzie AE, Young IM, Tanglay O, Briggs RG, Chakraborty AR, Hormovas J, Fonseka RD, Kim SJ, Yeung JT, Teo C, Sughrue ME. Anatomy and White Matter Connections of the Parahippocampal Gyrus. World Neurosurgery 2021, 148: e218-e226. PMID: 33412321, DOI: 10.1016/j.wneu.2020.12.136.Peer-Reviewed Original Research
2020
The Surgical Resection of Brainstem Glioma: Outcomes and Prognostic Factors
Faulkner H, Arnaout O, Hoshide R, Young IM, Yeung JT, Sughrue ME, Teo C. The Surgical Resection of Brainstem Glioma: Outcomes and Prognostic Factors. World Neurosurgery 2020, 146: e639-e650. PMID: 33152495, DOI: 10.1016/j.wneu.2020.10.147.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAstrocytomaAtaxiaBrain Stem NeoplasmsCerebrospinal Fluid LeakChildChild, PreschoolDiplopiaEpendymomaFemaleGlioblastomaGliomaHeadacheHumansHydrocephalusInfantInfant, NewbornKaplan-Meier EstimateKarnofsky Performance StatusMachine LearningMagnetic Resonance ImagingMaleMiddle AgedMultivariate AnalysisNauseaNeoplasm GradingNeoplasm, ResidualNeurosurgical ProceduresPostoperative ComplicationsPrognosisRetrospective StudiesSurvival RateTumor BurdenVomitingYoung AdultConceptsBrainstem gliomasSurgical resectionPrognostic factorsSurgical treatmentTransient neurologic deficitsRadical surgical resectionHigh-grade tumorsPostoperative radiographic evaluationMagnetic resonance imagingChart reviewNeurologic deficitsOverall survivalSurgical candidatesConfers survival advantageMedian ageSurgical indicationsPatient selectionSurvival outcomesRadiographic evaluationSelect subgroupRadiographic featuresPrimary treatmentPermanent deficitsSurvival advantageTreatment selectionClinical and economic burden of neurofibromatosis type 2 in the United States
Koo AB, Yeung JT, Freedman IG, Lee JH, Ahmed OM, Ma AK, Miyagishima DF, DiLuna M, Kahle K. Clinical and economic burden of neurofibromatosis type 2 in the United States. Clinical Neurology And Neurosurgery 2020, 197: 106053. PMID: 32683193, DOI: 10.1016/j.clineuro.2020.106053.Peer-Reviewed Original ResearchConceptsOpen resectionPatient demographicsRisk factorsMeningioma resectionMulti-year cross-sectional studyNeurofibromatosis type 2 (NF2) patientsSpine tumor resectionCommon admission diagnosesNational Inpatient SampleType 2 patientsCross-sectional studySignificant independent associationNeurofibromatosis type 2Regression analysisInflation-adjusted costAdmission diagnosisHospital stayDischarge weightIndependent predictorsObstructive hydrocephalusSurgical interventionDiagnosis codesHospital characteristicsInpatient populationInpatient SampleIn silico analysis of the immunological landscape of pituitary adenomas
Yeung JT, Vesely MD, Miyagishima DF. In silico analysis of the immunological landscape of pituitary adenomas. Journal Of Neuro-Oncology 2020, 147: 595-598. PMID: 32236778, PMCID: PMC7261241, DOI: 10.1007/s11060-020-03476-x.Peer-Reviewed Original ResearchConceptsPituitary adenomasImmunological landscapeImmune cellsM2 macrophagesPituitary tumorsAdenoma subtypesSilent pituitary tumorsMemory T cellsImmune cell typesDifferent immunotherapiesHigh CD8Immune infiltratesImmune landscapeSilent tumorsGH tumorsImmunological compositionMacrophage fractionT cellsMast cellsTumor subtypesSolid tumorsSubclinical casesAdenomasTumorsSubtypes
2016
Impact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor–Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases
Magnuson WJ, Yeung JT, Guillod PD, Gettinger SN, Yu JB, Chiang VL. Impact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor–Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases. International Journal Of Radiation Oncology • Biology • Physics 2016, 95: 673-679. PMID: 27034176, DOI: 10.1016/j.ijrobp.2016.01.037.Peer-Reviewed Original ResearchConceptsWhole-brain radiation therapyUpfront EGFR-TKIIntracranial progression-free survivalUpfront radiation therapyProgression-free survivalBrain metastasesEGFR-TKI groupEGFR-TKIEGFR-mutant NSCLCOverall survivalRadiation therapyEpidermal Growth Factor Receptor–Mutant NonDisease-specific Graded Prognostic AssessmentUpfront EGFR tyrosine kinase inhibitorsEGFR-TKI resistance mutationSmall cell lung cancerEGFR tyrosine kinase inhibitorsEGFR-TKI useMedian overall survivalSimilar overall survivalUpfront RT groupInferior overall survivalCell lung cancerMutant lung adenocarcinomaEpidermal growth factor receptor
2014
Hemifacial Spasm and Neurovascular Compression
Lu AY, Yeung JT, Gerrard JL, Michaelides EM, Sekula RF, Bulsara KR. Hemifacial Spasm and Neurovascular Compression. The Scientific World JOURNAL 2014, 2014: 349319. PMID: 25405219, PMCID: PMC4227371, DOI: 10.1155/2014/349319.Peer-Reviewed Original ResearchConceptsHemifacial spasmMicrovascular decompressionMagnetic resonance imagingSymptomatic reliefFacial nerveNerve root entry zonePrimary hemifacial spasmSecondary hemifacial spasmBotulinum neurotoxin injectionStandard medical managementTreatment of choiceFacial nerve rootRoot entry zoneIpsilateral facial nerveFacial nerve damageFacial movement disordersHFS patientsNerve damageVascular compressionCurative treatmentMedical managementNerve rootsNeurovascular compressionSurgical interventionClinical examination
2013
LOH in the HLA Class I Region at 6p21 Is Associated with Shorter Survival in Newly Diagnosed Adult Glioblastoma
Yeung JT, Hamilton RL, Ohnishi K, Ikeura M, Potter DM, Nikiforova MN, Ferrone S, Jakacki RI, Pollack IF, Okada H. LOH in the HLA Class I Region at 6p21 Is Associated with Shorter Survival in Newly Diagnosed Adult Glioblastoma. Clinical Cancer Research 2013, 19: 1816-1826. PMID: 23401227, PMCID: PMC3618546, DOI: 10.1158/1078-0432.ccr-12-2861.Peer-Reviewed Original ResearchConceptsHLA class IT cell infiltrationHLA class IILoss of heterozygosityHLA class IIIClass IOverall survivalAdult glioblastomaClass IIIHLA class I expressionHuman leukocyte antigen (HLA) class IClass IIEfficacy of immunotherapyShorter overall survivalCytotoxic T cellsClass I expressionAntigen class ICross-sectional analysisAdult patientsShorter survivalImmunohistochemical evaluationT cellsHLA class I regionI expressionDownregulated expression
2012
Increased expression of tumor-associated antigens in pediatric and adult ependymomas: implication for vaccine therapy
Yeung JT, Hamilton RL, Okada H, Jakacki RI, Pollack IF. Increased expression of tumor-associated antigens in pediatric and adult ependymomas: implication for vaccine therapy. Journal Of Neuro-Oncology 2012, 111: 103-111. PMID: 23179498, PMCID: PMC3546121, DOI: 10.1007/s11060-012-0998-x.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge FactorsAgedAged, 80 and overAntigens, NeoplasmBrainBrain NeoplasmsCancer VaccinesChildChild, PreschoolEpendymomaFemaleGene Expression Regulation, NeoplasticHistocompatibility Antigens Class IHumansInfantInhibitor of Apoptosis ProteinsInterleukin-13 Receptor alpha1 SubunitMaleMiddle AgedReceptor, EphA2SurvivinWT1 ProteinsConceptsTumor-associated antigensMore tumor-associated antigensIL-13Rα2Positive stainingAdult ependymomasMultiple peptides vaccineNormal brain tissueGlioma vaccinesImmunotherapy approachesVaccine therapyPediatric casesAdult casesTumor recurrenceClinical trialsPeptide vaccinePediatric ependymomaNormal brainEpendymomaBrain tissuePediatric gliomasTumor 1SurvivinStainingEphA2VaccinePegylated interferon-α-2b for children with recurrent craniopharyngioma.
Yeung JT, Pollack IF, Panigrahy A, Jakacki RI. Pegylated interferon-α-2b for children with recurrent craniopharyngioma. Journal Of Neurosurgery Pediatrics 2012, 10: 498-503. PMID: 23061825, DOI: 10.3171/2012.9.peds12225.Peer-Reviewed Original ResearchConceptsMonths of treatmentGross total resectionPatient experienced recurrenceRecurrent craniopharyngiomaExperienced recurrenceSubtotal resectionComplete responseRadiation therapyUse of PIDisease 19 monthsDisease 6 monthsDisease 10 yearsInterferon α-2bStable diseaseDurable responsesIntralesional administrationCystic tumorTumor sizeTumor responseSubcutaneous injectionCystic componentFurther interventionCraniopharyngiomaRecurrenceSustained exposure